Expand Healthcare Consulting GmbH
Point of Care In Vitro Diagnostics Experts
Expand Healthcare Consulting GmbH
Point of Care In Vitro Diagnostics Experts
cMyC is a highly distinctive biomarker for cardiac necrosis, offering a superior solution for the early triage of chest pain patients. Unlike troponin, cMyC reaches detectable levels significantly faster in cases of Acute Myocardial Infarction (AMI), making it an ideal fit for Point-of-Care (PoC) platforms.
By enabling faster and more accurate risk stratification, cMyC has the potential to reduce the number of patients placed in observation units, directly translating to substantial cost savings for hospitals while improving patient flow and resource allocation.
Recent scientific publications have also demonstrated the clinical utility of cMyC in Acute Heart Failure, highlighting its potential to reshape cardiac diagnostics beyond AMI.
Discover how cMyC is set to redefine cardiac diagnostics. Reach out to learn more about its impact and commercial opportunities, or start by visiting the cMyC Cardiac Biomarker Website.